Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jul 24;83(4):463–466. doi: 10.1054/bjoc.2000.1249

The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel

A Vazina 1, J Baniel 1, Y Yaacobi 3, A Shtriker 3, D Engelstein 1, I Leibovitz 2, M Zehavi 4, A A Sidi 3, Y Ramon 2, T Tischler 4, P M Livne 1, E Friedman 5
PMCID: PMC2374645  PMID: 10945492

Abstract

Inherited predisposition occurs in 5–10% of all prostate cancer (CaP) patients, but the genes involved in conferring genetic susceptibility remain largely unknown. Several lines of evidence indicate that germline mutations in BRCA1 and BRCA2 might be associated with an increased risk for CaP. Three mutations in these two genes (185delAG and 5382InsC (BRCA1) and 6174delT (BRCA2) occur in about 2.5% of the general Ashkenazi population, and the 185delAG BRCA1 mutation, in up to 1% of non-Ashkenazi Jews. In order to assess the contribution of these germline mutations to prostate cancer in Jewish Israeli patients, we tested 174 unselected prostate cancer patients (95 of Ashkenazi origin) for these mutations by PCR amplification and modified restriction enzyme digests. Patient’s age range was 45–81 years (median 66), and in 24 (14.4%) the disease was diagnosed prior to 55 years of age. Nineteen (11%) and 12 (6.9%) patients had a first or second degree relative with CaP or breast cancer, respectively. Overall, five mutation carriers were detected: 2/152 (1.3%) 185delAG, 2/104 (2%) 5382InsC, and 1/158 (0.6%) 6174delT. In all carriers, the disease was diagnosed after the age of 55, and only one of them had a family history of breast and CaP. In addition, no allelic losses at the BRCA1 locus were demonstrated in 17 patients with a family history of CaP, using seven microsatellite markers. We conclude that the rate of the predominant Jewish BRCA1 and BRCA2 mutations in CaP patients does not significantly differ from that of the general population, and that mutational inactivation of the BRCA1 is rare in familial CaP. Thus, germline BRCA1 and BRCA2 mutations probably contribute little to CaP occurrence, to inherited predisposition, and to early onset disease in Jewish individuals. © 2000 Cancer Research Campaign

Full Text

The Full Text of this article is available as a PDF (89.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abeliovich D., Kaduri L., Lerer I., Weinberg N., Amir G., Sagi M., Zlotogora J., Heching N., Peretz T. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet. 1997 Mar;60(3):505–514. [PMC free article] [PubMed] [Google Scholar]
  2. Anderson D. E., Badzioch M. D. Familial effects of prostate and other cancers on lifetime breast cancer risk. Breast Cancer Res Treat. 1993 Nov;28(2):107–113. doi: 10.1007/BF00666423. [DOI] [PubMed] [Google Scholar]
  3. Arason A., Barkardóttir R. B., Egilsson V. Linkage analysis of chromosome 17q markers and breast-ovarian cancer in Icelandic families, and possible relationship to prostatic cancer. Am J Hum Genet. 1993 Apr;52(4):711–717. [PMC free article] [PubMed] [Google Scholar]
  4. Bar-Sade R. B., Kruglikova A., Modan B., Gak E., Hirsh-Yechezkel G., Theodor L., Novikov I., Gershoni-Baruch R., Risel S., Papa M. Z. The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim. Hum Mol Genet. 1998 May;7(5):801–805. doi: 10.1093/hmg/7.5.801. [DOI] [PubMed] [Google Scholar]
  5. Carter B. S., Beaty T. H., Steinberg G. D., Childs B., Walsh P. C. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3367–3371. doi: 10.1073/pnas.89.8.3367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Deubler D. A., Williams B. J., Zhu X. L., Steele M. R., Rohr L. R., Jensen J. C., Stephenson R. A., Changus J. E., Miller G. J., Becich M. J. Allelic loss detected on chromosomes 8, 10, and 17 by fluorescence in situ hybridization using single-copy P1 probes on isolated nuclei from paraffin-embedded prostate tumors. Am J Pathol. 1997 Mar;150(3):841–850. [PMC free article] [PubMed] [Google Scholar]
  7. Easton D. F., Ford D., Bishop D. T. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995 Jan;56(1):265–271. [PMC free article] [PubMed] [Google Scholar]
  8. Easton D. F., Steele L., Fields P., Ormiston W., Averill D., Daly P. A., McManus R., Neuhausen S. L., Ford D., Wooster R. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet. 1997 Jul;61(1):120–128. doi: 10.1086/513891. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ford D., Easton D. F., Bishop D. T., Narod S. A., Goldgar D. E. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994 Mar 19;343(8899):692–695. doi: 10.1016/s0140-6736(94)91578-4. [DOI] [PubMed] [Google Scholar]
  10. Futreal P. A., Cochran C., Rosenthal J., Miki Y., Swenson J., Hobbs M., Bennett L. M., Haugen-Strano A., Marks J., Barrett J. C. Isolation of a diverged homeobox gene, MOX1, from the BRCA1 region on 17q21 by solution hybrid capture. Hum Mol Genet. 1994 Aug;3(8):1359–1364. doi: 10.1093/hmg/3.8.1359. [DOI] [PubMed] [Google Scholar]
  11. Gittes R. F. Carcinoma of the prostate. N Engl J Med. 1991 Jan 24;324(4):236–245. doi: 10.1056/NEJM199101243240406. [DOI] [PubMed] [Google Scholar]
  12. Greer C. E., Peterson S. L., Kiviat N. B., Manos M. M. PCR amplification from paraffin-embedded tissues. Effects of fixative and fixation time. Am J Clin Pathol. 1991 Feb;95(2):117–124. doi: 10.1093/ajcp/95.2.117. [DOI] [PubMed] [Google Scholar]
  13. Hubert A., Peretz T., Manor O., Kaduri L., Wienberg N., Lerer I., Sagi M., Abeliovich D. The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet. 1999 Sep;65(3):921–924. doi: 10.1086/302525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Isaacs S. D., Kiemeney L. A., Baffoe-Bonnie A., Beaty T. H., Walsh P. C. Risk of cancer in relatives of prostate cancer probands. J Natl Cancer Inst. 1995 Jul 5;87(13):991–996. doi: 10.1093/jnci/87.13.991. [DOI] [PubMed] [Google Scholar]
  15. Johannesdottir G., Gudmundsson J., Bergthorsson J. T., Arason A., Agnarsson B. A., Eiriksdottir G., Johannsson O. T., Borg A., Ingvarsson S., Easton D. F. High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res. 1996 Aug 15;56(16):3663–3665. [PubMed] [Google Scholar]
  16. Knudson A. G., Jr Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971 Apr;68(4):820–823. doi: 10.1073/pnas.68.4.820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Langston A. A., Stanford J. L., Wicklund K. G., Thompson J. D., Blazej R. G., Ostrander E. A. Germ-line BRCA1 mutations in selected men with prostate cancer. Am J Hum Genet. 1996 Apr;58(4):881–885. [PMC free article] [PubMed] [Google Scholar]
  18. Lehrer S., Fodor F., Stock R. G., Stone N. N., Eng C., Song H. K., McGovern M. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Br J Cancer. 1998 Sep;78(6):771–773. doi: 10.1038/bjc.1998.576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Melamed J., Einhorn J. M., Ittmann M. M. Allelic loss on chromosome 13q in human prostate carcinoma. Clin Cancer Res. 1997 Oct;3(10):1867–1872. [PubMed] [Google Scholar]
  20. Schneider N. R., Chaganti S. R., German J., Chaganti R. S. Familial predisposition to cancer and age at onset of disease in randomly selected cancer patients. Am J Hum Genet. 1983 May;35(3):454–467. [PMC free article] [PubMed] [Google Scholar]
  21. Sellers T. A., Potter J. D., Rich S. S., Drinkard C. R., Bostick R. M., Kushi L. H., Zheng W., Folsom A. R. Familial clustering of breast and prostate cancers and risk of postmenopausal breast cancer. J Natl Cancer Inst. 1994 Dec 21;86(24):1860–1865. doi: 10.1093/jnci/86.24.1860. [DOI] [PubMed] [Google Scholar]
  22. Sheldon C. A., Williams R. D., Fraley E. E. Incidental carcinoma of the prostate: a review of the literature and critical reappraisal of classification. J Urol. 1980 Nov;124(5):626–631. doi: 10.1016/s0022-5347(17)55589-5. [DOI] [PubMed] [Google Scholar]
  23. Sigurdsson S., Thorlacius S., Tomasson J., Tryggvadottir L., Benediktsdottir K., Eyfjörd J. E., Jonsson E. BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med (Berl) 1997 Oct;75(10):758–761. doi: 10.1007/s001090050162. [DOI] [PubMed] [Google Scholar]
  24. Struewing J. P., Hartge P., Wacholder S., Baker S. M., Berlin M., McAdams M., Timmerman M. M., Brody L. C., Tucker M. A. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997 May 15;336(20):1401–1408. doi: 10.1056/NEJM199705153362001. [DOI] [PubMed] [Google Scholar]
  25. Tulinius H., Egilsson V., Olafsdóttir G. H., Sigvaldason H. Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. BMJ. 1992 Oct 10;305(6858):855–857. doi: 10.1136/bmj.305.6858.855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Watanabe M., Shiraishi T., Muneyuki T., Nagai M., Fukutome K., Murata M., Kawamura J., Yatani R. Allelic loss and microsatellite instability in prostate cancers in Japan. Oncology. 1998 Nov-Dec;55(6):569–574. doi: 10.1159/000011914. [DOI] [PubMed] [Google Scholar]
  27. Whittemore A. S., Wu A. H., Kolonel L. N., John E. M., Gallagher R. P., Howe G. R., West D. W., Teh C. Z., Stamey T. Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol. 1995 Apr 15;141(8):732–740. doi: 10.1093/oxfordjournals.aje.a117495. [DOI] [PubMed] [Google Scholar]
  28. Wilkens E. P., Freije D., Xu J., Nusskern D. R., Suzuki H., Isaacs S. D., Wiley K., Bujnovsky P., Meyers D. A., Walsh P. C. No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer. Prostate. 1999 Jun 1;39(4):280–284. doi: 10.1002/(sici)1097-0045(19990601)39:4<280::aid-pros8>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  29. Williams B. J., Jones E., Zhu X. L., Steele M. R., Stephenson R. A., Rohr L. R., Brothman A. R. Evidence for a tumor suppressor gene distal to BRCA1 in prostate cancer. J Urol. 1996 Feb;155(2):720–725. [PubMed] [Google Scholar]
  30. Williams B. J., Jones E., Zhu X. L., Steele M. R., Stephenson R. A., Rohr L. R., Brothman A. R. Evidence for a tumor suppressor gene distal to BRCA1 in prostate cancer. J Urol. 1996 Feb;155(2):720–725. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES